BioCentury
ARTICLE | Product R&D

Enter GammaDelta

How GammaDelta's T cells could become the newest cancer immunotherapy class

September 15, 2016 7:00 AM UTC

Today's launch of Abingworth-backed GammaDelta Therapeutics Ltd. could signal the rise of γδ T cells as the newest class of cancer immunotherapies. The company is the second founded in as many years to capitalize on the small subclass that Abingworth believes could outstrip the more common αβ T cells filling company pipelines.

Abingworth will incubate GammaDelta in its London offices and is providing an undisclosed amount of seed funding...